TAMI Industries brings high-tech ceramic membranes to UK market

Coline BORDET - 21-janv.-2014 16:51:26
TAMI Industries of France is a leader in filtration technology and a specialist in advanced ceramic membranes used across a wide range of industries: the company is looking for partners in the UK, where it wants to develop its business. TAMI Industries already has subsidiaries in Germany, North America, China and Mexico, with 90% of its sales coming from exports.   The ceramic membranes developed by TAMI Industries are a high-performance product with elevated permeability, wide-range selectivity, superior mechanical resistance, and high chemical/thermal stability. TAMI Industries is currently seeking partners in the UK for the promotion and the technical support of its range of products and technologies.   TAMI Industries’ R&D department is constantly working on the development of new inorganic membranes: this sustained investment in research and development on the part of TAMI Industries has resulted in the design and development of patented high-tech tubular ceramic membranes that have truly unique characteristics.   The advantage of the non-circular filtering channels adopted by TAMI Industries — channels that are geometrically shaped like petals — is that they allow for the optimization of the filtration performance. While maintaining a standard outside diameter of the membrane, the filtration surface area is thus made larger. Additionally, TAMI industries has upgraded to titanium dioxide in the fabrication of its membranes — a material that is bio-compatible, with the added benefit that it is highly resistant to a wide range of chemical agents. At present, TAMI Industries is the only manufacturer capable of producing this type of high-performance ceramic membrane on an industrial scale.   Thanks to such technological advances, it is possible to cut energy costs while reducing exploitation and maintenance costs too. In addition, the dimensions of the membranes developed by TAMI Industries are compatible with all existing installations equipped with ceramic membranes, which allows for the easy upgrading of existing industrial plants: this can be done through the replacement of the existing membranes, or thanks to a retrofitting process.   Among the industrial processes of separation, the use of ceramic membranes has become more and more common in recent years. In spite of accounting for only 10% of the crossflow filtration market worldwide, ceramic membranes are often in competition with organic membranes. However, ceramic membranes have the advantage that they ensure improved performance and durability. It should also be stressed that ceramic membranes have a high resistance to many corrosive chemical solutions and superior tolerance to an array of temperatures and pH values, while providing excellent mechanical resistance to pressure.   Key applications for TAMI Industries’ ceramic membranes can be found across a diverse range of sectors. In the food-and-drink industry, ceramic membranes can be used in the cold debacterialization of milk as well as the fractionation, standardization and concentration of milk proteins and lactoserum (WPI/ WPC). Such membranes are also used in the clarification of juices (made out of fruit or vegetables), wine, cider and sweet juices.   In the pharmaceuticals and bio-industrial sectors, ceramic membranes are essential in the clarification of fermentation broths — for the production of organic acids, antibiotics, enzymes, vitamins, etc. — and in the production of natural extracts from plants, including seaweed.   Finally, in the environmental sector, ceramic membranes are key in the treatment of industrial effluents and, also, in the separation of oily water emulsions. Other applications include the treatment of laundry wastewater and the processing of effluents generated by paper mills, ink-printing processes and the textile industry, among others.   About TAMI Industries   TAMI Industries designs, develops and manufactures industrial inorganic filters (known as membranes) for the separation of molecules contained within liquids by way of fine ultra-filtration, ultra-filtration, and microfiltration. TAMI Industries controls the whole of the filters’ production process, from membrane design to the manufacturing of supports and the application of active filtration layers.   TAMI Industries, which is headquartered in Nyons (South-Eastern France), is a global player in the field of filtration, with 90% of the company’s turnover coming from export markets. TAMI Industries currently has four subsidiaries outside France: in Canada, China, Germany and Mexico. The company is keen to develop its activities in the United Kingdom.   For further information, please go to:       For further information, please contact :   Quote ref. : FTPB3891 Ms Kate RILEY - Press Officer UBIFRANCE Press Office in London Tel: +44 (0) 207 024 3640 View other press releases at :  

World HAI Forum lists priorities for fighting bacterial antibiotic resistance

Pierre Mancini - 11-juil.-2011 10:56:39
  Annecy (France), 8 July 2011 — Over 70 international experts in medicine, infectious diseases, microbiology and epidemiology, coming from every continent, gathered at the Fondation Mérieux’s Conference Center in Annecy (France) between 27 and 29 June 2011 for the third World HAI Forum on healthcare-associated infections, a biennial bioMérieux initiative. The Forum’s participants warned of an impending public-health catastrophe caused by the emergence and spread of bacteria that are resistant to all antibiotics, if no action is taken.     The delegates at the third World HAI Forum on healthcare-associated infections — a bioMérieux initiative taking place every two years — called upon national and international health authorities and policy makers, the medical and veterinary communities, industry, and the general public to take urgent action in order to avert potentially disastrous developments in public health, with the emergence and spread of multidrug-resistant bacteria.   While research to discover novel antibiotics has slowed to a virtual standstill, bacterial resistance has increased due to the massive use and misuse of antibiotics, not only for human health, but also for animals. The treatment of certain common infections is becoming difficult and the success of immunosuppressive therapies and surgical interventions (such as organ transplants and cardiac surgery), which are associated with a high risk of bacterial infection, could be compromised.   To the Forum’s experts, the emergence of pan-resistant NDM-1 bacteria and the epidemic of multidrug-resistant E. coli infections, currently affecting Europe, should be taken as a major public-health warning, indicating that a new era of antimicrobial resistance has begun. This must lead to a global awakening: the protection of antibiotics has now entered the sphere of sustainable development.   In a continuation of calls to action and proposals made by major national and international organizations (WHO, ECDC, IDSA, CDC, etc.), the Forum’s participants identified priority action areas to fight bacterial resistance and recommended 12 very concrete actions to be implemented, in the short to medium term, to effectively address this serious problem.   • Priority actions for policy makers and health authorities   -For animals, stop the administration of antibiotics used in human medicine and limit antibiotics to therapeutic use only. It is imperative to reserve the most important classes of antibiotics for humans.   -Banish, in all countries, the use of antibiotics as growth promoters in animal feed.   -Regulate the sale of antibiotics for use in human medicine and prohibit over-the-counter sales worldwide.   -Have international organizations (WHO, European Union) develop a charter on good antibiotic stewardship and have all the ministries of health worldwide sign it and commit to respecting it.   • Priority actions for the human and veterinary healthcare communities   -Establish standardized, universal surveillance of antibiotic use and resistance and monitor the emergence and spread of new forms of bacterial resistance.   -Include, in the medical- and veterinary-school curricula, a solid training in bacterial resistance and the prudent use of antibiotics and establish on-the-job training programmes for healthcare workers, taking into account the cultural specificities of each country.   • Priority actions for the general public   -Develop culturally sensitive awareness campaigns, targeted to the general public, explaining the importance of protecting antibiotics and using them only when absolutely necessary.   -Provide education about fundamental hygiene, such as hand-washing, to prevent the spread of infection. It is imperative to improve sanitation systems to eliminate resistant bacteria in wastewater.   -Include consumers in the development and implementation of action plans.   • Priority actions for industry   -Develop Point-of-Care and rapid diagnostic tests, which can be used at the patient’s bedside or the doctor’s office, to guide the prescription of antibiotics and avoid their prescription for viral infections.   -Stimulate research and development of novel antibiotics.   -Find new economic models, which reconcile public-health interests with industry needs for profitability.   About the World HAI Forum   The third biennial World HAI Forum took place in Annecy (in south-eastern France) from 27 to 29 June 2011. The Forum was characterized by the exceptional geographical diversity of its participants, coming from 33 countries.    While most such meetings focus on scientific developments retrospectively, in an academic format, the World HAI Forum, which is held every two years, gives participating experts a chance to do prospective analysis of subjects that are not usually discussed. More time is devoted to sharing best practices, successes and failures in the fight against multidrug-resistant bacteria, as a basis for building effective action plans.   A world leader in microbiology and a pioneer in resistance detection and susceptibility testing, bioMérieux works closely with healthcare professionals in the three key areas of infection control — prevention, surveillance and intervention. Diagnostic tests are paramount to success in the fight against infections with resistant bacteria.   As part of its commitment to fight hospital-acquired infections (HAIs) and microbial resistance, bioMérieux has also held HAI symposia around the world over the past three years, in countries including Belgium, China, Colombia, Japan, the Netherlands, Portugal, Saudi Arabia, South Korea, Spain and the United States.   To hear what experts discussed at the Forum, please go to:   For further information about the Forum, please go to:   About bioMérieux   • Advancing Diagnostics to Improve Public Health   A world leader in the field of in vitro diagnostics for over 45 years, bioMérieux is present in more than 150 countries through 39 subsidiaries and a large network of distributors. In 2010, revenues reached €1,357 billion, with 87% of sales outside France.   bioMérieux provides diagnostic solutions (reagents, instruments and software), which determine the source of disease and contamination to improve patient health and ensure consumer safety. The company’s products are used for diagnosing infectious diseases and providing high-medical-value results for cancer screening and monitoring, and for cardiovascular emergencies. bioMérieux’s solutions are also used for detecting micro-organisms in agri-food, pharmaceutical and cosmetic products.   bioMérieux is listed on the NYSE Euronext Paris stock exchange (Symbol: BIM – ISIN: FR0010096479).   For further information about bioMérieux, please go to:  
  Business France is the national agency supporting the international development of the French economy, responsible for fostering export growth by French businesses, as well as promoting and facilitating international investment in France. It promotes France’s companies, business image and nationwide attractiveness as an investment location, and also runs the VIE international internship program. Founded on January 1, 2015 through a merger between UBIFRANCE and the Invest in France Agency, Business France has 1,500 personnel, both in France and in 70 countries throughout the world, who work with a network of public- and private-sector partners.   Business France’s three missions are: - Fostering export growth by French businesses. - Promoting and facilitating international investment in France. - Promoting France’s companies, business image and nationwide attractiveness as an investment location.     These missio



           Business France



            About the French know how :




    Rail industry


    French Healthcare


Press area & Media Gallery
Latest comments